All In Biotech

Drug Trial Radar · NCT06563999

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Neoadjuvant Umbrella Trial Directed by Next Generation Sequencing for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations (Without EGFR Sensitizing Mutations)

Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Nov 1, 2024

Primary completion

Nov 1, 2027

Study completion Nov 1, 2029

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC). The aim of the umbrella study is to evaluate the efficacy of induction NGS-directed targeted therapies followed by surgery for stage III NSCLC patients whose tumor harbors a rare mutation.

Conditions

  • Lung Cancer Stage III
  • Mutation

Interventions

  • SunvozertinibDrug

    300 mg orally once a day, 28 days as one cycle.

  • CrizotinibDrug

    300 mg orally once a day, 28 days as one cycle.

  • PralsetinibDrug

    400 mg orally once a day, 28 days as one cycle.

  • LarotrectinibDrug

    100 mg orally twice daily, 28 days as one cycle.

  • SavolitinibDrug

    600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.

  • PyrotinibDrug

    400 mg orally once a day, 28 days as one cycle.

  • Dabrafenib+TrametinibDrug

    Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.

  • GlecirasibDrug

    800 mg daily orally, 28 days as one cycle.

  • EnsartinibDrug

    225 mg daily orally, 28 days as one cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Resectability rateTime frame: Baseline to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.